Earnings call briefThird-quarter 2026
Viking Therapeutics expects average cash use of around $100 million a quarter
CFO Gregory Zante also said general and administrative expense should be fairly flat near term, probably picking up closer to commercialization.
GetSignal Viking Therapeutics VKTX
CFO Gregory Zante said on the third-quarter call that the company expects average cash use of around $100 million a quarter, with some quarters higher and some lower. He said general and administrative expense would be fairly flat in the near term and would probably pick up later, closer to commercialization.
He said the company's $960 million cash balance includes aggregate net proceeds of approximately $550 million from the recent financing.
Quotes from the call
“...I think as we think about cash, just company-wide, I think we'd see a usage of average of around $100 million per quarter.”
Key facts from the call
- Expected average quarterly cash use
- Around $100 million, with some quarters higher and some lower
- Net proceeds from recent financing
- Approximately $550 million
Source: Viking Therapeutics' third-quarter 2026 earnings call, October 28, 2026.
Written by GetSignal with AI from the company's earnings call.
Not investment advice.
More earnings call briefs
- Constellation Energy expects nuclear uprate costs of about $4.3 billion
CEG Constellation Energy Q3 2026 call
- Howard Hughes Holdings says its insurance ambition is a return on equity in excess of 20%
HHH Howard Hughes Holdings Q3 2026 call
- Brookfield Asset Management now sees 2026 earnings modestly below early view
BAM Brookfield Asset Management Q3 2026 call
- Enbridge says it expects 2026 results at the midpoint of its guidance range
ENB Enbridge Q3 2026 call
- TeraWulf sees about half of contracted IT capacity earning revenue by end of Q1
WULF TeraWulf Q3 2026 call
